System and method for verifying optical code reads and RFID reads

Details for Australian Patent Application No. 2003297246 (hide)

Owner Symbol Technologies, Inc.

Inventors He, Duanfeng

Agent Spruson & Ferguson

Pub. Number AU-B-2003297246

PCT Number PCT/US2003/0401

PCT Pub. Number WO2004/059563

Priority 60/434,519 18.12.02 US; 10/621,295 17.07.03 US; 10/385,941 11.03.03 US

Filing date 17 December 2003

Wipo publication date 22 July 2004

Acceptance publication date 29 November 2007

International Classifications

G06K 7/00 (2006.01) Methods or arrangements for sensing record carriers

G06K 7/10 (2006.01) Methods or arrangements for sensing record carriers - by electromagnetic radiation, e.g. optical sensing

G06K 9/22 (2006.01) Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints - using hand-held instruments

G06K 19/14 (2006.01) Record carriers for use with machines and with at least a part designed to carry digital markings - the marking being sensed by radiation

Event Publications

6 May 2004 Complete Application Filed

  Priority application(s): 60/434,519 18.12.02 US; 10/621,295 17.07.03 US; 10/385,941 11.03.03 US

26 August 2004 Application Open to Public Inspection

  Published as AU-B-2003297246

29 November 2007 Application Accepted

  Published as AU-B-2003297246

3 April 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003297247-A BIASED SOCKET CONTACT AND A METHOD THEREOF

2003297245-METHOD OF USING A COX-2 INHIBITOR AND A TOPOISOMERASE II INHIBITOR AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA